Evidence map›Paper›PMID 25854649›Full record

ArticleCurrent treatment options in neurology2015

Acute management of brain arteriovenous malformations.

Andreas Hartmann, J P Mohr

Abstract read
PubMed Publisher
In one paragraph

Article in Current treatment options in neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Pediatric Brain AVM: The Role of DSA During Surgery in Hybrid Operating Room.Advances and technical standards in neurosurgery · 2026
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Andreas HartmannDepartment of Neurology, Klinikum Frankfurt (Oder), Müllroser Chaussee 7, 15236, Frankfurt (Oder) and Charité Berlin, Germany, andreas.hartmann@klinikumffo.de.
J P Mohr
Columbia University Irving Medical Center · USKlinikum Frankfurt Höchst · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementMajor reasons to treat brain arteriovenous malformations (AVMs) are to reduce the risk of brain hemorrhage, control intractable seizure, and in some cases alleviate neurologic deficits. Once an AVM has hemorrhaged, the risk of further hemorrhage is increased and it should be treated. The treatment plan ideally is based on interdisciplinary discussion between neurosurgery, endovascular neuroradiology, and radiotherapy, moderated by neurology in an experienced center. Complete removal or obliteration of the malformation should be the goal, as partial treatment only exposes the patient to treatment risks with a residual hemorrhage risk. If an AVM is surgically accessible with acceptable treatment risk, neurosurgical removal leads to the fastest and most complete reduction of hemorrhage risk. Radiotherapy is best used in small AVMs with contraindications to surgery. Endovascular embolization can be used as an adjunct for both to facilitate removal or obliteration or to reduce risks from associated aneurysms or high-flow fistulae, and may in some cases lead to complete occlusion. Unbled AVMs require a thorough assessment of projected hemorrhage risk versus treatment risks, as the natural course is influenced by clinical and morphological factors. Given recent scientific evidence, those with low projected hemorrhage risks should be managed conservatively, receiving the best medical treatment of accompanying symptoms, and careful clinical and follow-up imaging monitoring. Thorough and objective counselling of the patients about pros and contras of therapy, detailed explanation of recommendations, and possible reevaluation of treatment decisions at later timepoints are recommended.

Identifiers

PMID25854649
OpenAlexW2010905950

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.